Movatterモバイル変換

[0]ホーム

Jump to content

MCOPPB

Edit links

From Wikipedia, the free encyclopedia

Chemical compound

Pharmaceutical compound

MCOPPB
Identifiers

IUPAC name 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole
CAS Number	1028969-49-4^Y trihydrochloride: 1108147-88-1^Y
PubChemCID	24800108
ChemSpider	21378267
UNII	8NMK0UG3HV trihydrochloride: SIO8DBP4K7^Y
CompTox Dashboard(EPA)	DTXSID401018254
Chemical and physical data
Formula	C₂₆H₄₀N₄
Molar mass	408.634 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1(CCCCCCC1)N2CCC(CC2)N3C4=CC=CC=C4N=C3[C@@H]5CCCNC5
InChI InChI=1S/C26H40N4/c1-26(15-7-3-2-4-8-16-26)29-18-13-22(14-19-29)30-24-12-6-5-11-23(24)28-25(30)21-10-9-17-27-20-21/h5-6,11-12,21-22,27H,2-4,7-10,13-20H2,1H3/t21-/m1/s1 Key:CYYNMPPFEJPBJD-OAQYLSRUSA-N

MCOPPB is a drug which acts as a potent and selective agonist for thenociceptin receptor, with a pKi of 10.07 and much weaker activity at other opioid receptors. It has only moderate affinity for themu opioid receptor, weak affinity for thekappa opioid receptor and negligible binding at thedelta opioid receptor. In animal studies, MCOPPB produces potentanxiolytic effects, with no inhibition of memory or motor function, and only slight sedative side effects which do not appear until much higher doses than the effective anxiolytic dose range.^[1]^[2]

References

[edit]

^Hirao A, Imai A, Sugie Y, Yamada Y, Hayashi S, Toide K (March 2008)."Pharmacological characterization of the newly synthesized nociceptin/orphanin FQ-receptor agonist 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole as an anxiolytic agent".Journal of Pharmacological Sciences.106 (3):361–8.doi:10.1254/jphs.fp0071742.PMID 18319566.
^Hayashi S, Hirao A, Imai A, Nakamura H, Murata Y, Ohashi K, Nakata E (February 2009). "Novel non-peptide nociceptin/orphanin FQ receptor agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: design, synthesis, and structure-activity relationship of oral receptor occupancy in the brain for orally potent antianxiety drug".Journal of Medicinal Chemistry.52 (3):610–25.doi:10.1021/jm7012979.PMID 19125610.